Figure 1.

WSG enhances the cytotoxic effects of cisplatin on A549 and LLC1 cells. (A) A549 and LLC1 cells were subjected to 24 h combination treatment using different concentrations of WSG and cisplatin. A crystal violet staining assay was conducted for cell viability examination. Each sample in the combination treatment group was normalized against each untreated control. (B,C) CI and DRI of the combination treatment in the A549 and LLC1 cells, determined using CompuSyn software. (D) WSG reduced the IC₅₀ of cisplatin in A549 and LLC1 cells. The IC₅₀ values of cisplatin were measured using CompuSyn Software. Significant differences between the treatment and control groups are presented (*** p < 0.001). (E) Left: the schematic design for the in vitro cell viability assay of WSG (0–360 μg/mL)→cisplatin (5 μM) sequential treatment. Right: The viability of the cells was determined by using the crystal violet assay. (F) Left: the schematic design for the in vitro cell viability assay of cisplatin (5 μM)→WSG (0–360 μg/mL) sequential treatment. Right: The viability of the cells was determined by using the crystal violet assay. Each sample in the combination treatment group was normalized against each untreated control. Error bars indicated SD.